

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hua Han Bio-Pharmaceutical Holdings Limited
華瀚生物製藥控股有限公司
(incorporated in the Cayman Islands with limited liability)

(Stock Code: 587)

VOLUNTARY ANNOUNCEMENT ACQUISITION OF SHARES BY A SUBSTANTIAL SHAREHOLDER

The board (“Board”) of directors (“Directors”) of Hua Han Bio-Pharmaceutical Holdings Limited (“Company”) wishes to announce that the Company was informed by Bull’s-Eye Limited which is beneficially owned by Mr. Zhang Peter Y. and Mr. Deng Jie, that Bull’s-Eye Limited acquired 7,860,000 shares of the Company on 29 June 2015 from open market purchase. Following such acquisition, Bull’s-Eye Limited held 1,930,442,643 shares of the Company, representing approximately 26.19% of the existing issued share capital of the Company as at the date of this announcement.

This announcement is made by the Company on a voluntary basis.

By Order of the Board
Hua Han Bio-Pharmaceutical Holdings Limited
Zhang Peter Y.
Chairman

Hong Kong, 30 June 2015

As at the date of this announcement, the Board comprises Mr. Zhang Peter Y., Mr. Deng Jie, Mr. Long Xian Feng and Mr. Zhou Chong Ke as executive Directors, Mr. Wee Ee Lim (Ms. Lim Seok Bin Zann as his alternate) and Mr. Tarn Sien Hao as non-executive Directors, and Professor Kung Hsiang Fu, Professor Tso Wung Wai and Mr. Hon Yiu Ming Matthew as independent non-executive Directors.